A decreased T cell function can be demonstrated in approximately 50% of patients with cancer. The molecular basis for the diminished T cell response appears to be in part a decreased expression of signal transduction proteins in T cells, caused by mechanisms that remain unclear. Possible explanations have included the production of oxygen radicals by macrophages or the induction of apoptosis following the interaction of Fas ligand from the tumor cells with Fas-receptor in T cells. Alternatively, we proposed that """"""""chronic stimulation of T cells by antigen, in the absence of co-stimulatory signals, can lead to the decreased expression of T cell signal transduction proteins"""""""". Results obtained during the past grant period supported this hypothesis and revealed a new and as yet undescribed mechanism that can regulate T cell signal transduction and function in patients with cancer: The data demonstrates that L-arginine, a semi-essential amino-acid, regulates the expression of CD3zeta, Jak-3 and NF-kappaBp65, and thereby modifies T cell proliferation and the production of cytokines such as IFNgamma. Arginine levels are in turn closely controlled by arginase I, an enzyme produced by tumor cells and macrophages. The co-culture of T cells with arginase producing cells reproduces in vitro most of the changes previously described in patients making this an optimal model to study this complex phenomenon. Therefore the hypotheses for the next project period are: (A) arginase produced by tumor cells or macrophages in cancer patients, depletes arginine, which induces a decreased expression of certain T cell signal transduction molecules and results in a decreased T cell function. (B) This in turn can impair the anti-tumor effect of immunotherapy. To test these hypotheses we propose the following specific aims: ? ? 1 Test specific molecular mechanisms by which low concentrations of L-arginine regulate the expression and function of T cell signal transduction proteins and affect specific T cell functions.2.Test the prediction that arginase produced by tumor cells or macrophages regulates the availability of arginine and thereby alters T cell signal transduction.3.Test in tumor bearing mice the effects of arginase production on tumor growth, the response to immunotherapy and the potential use of arginase inhibitors as an adjuvant to immunotherapy.4.Test the prediction that arginase production in patients with cancer correlates with the presence of T cell signal transduction alterations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA082689-07
Application #
6927852
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Mccarthy, Susan A
Project Start
1999-08-01
Project End
2007-07-31
Budget Start
2005-08-25
Budget End
2006-07-31
Support Year
7
Fiscal Year
2005
Total Cost
$248,500
Indirect Cost
Name
Louisiana State University Hsc New Orleans
Department
Pediatrics
Type
Schools of Medicine
DUNS #
782627814
City
New Orleans
State
LA
Country
United States
Zip Code
70112
Hossain, Fokhrul; Al-Khami, Amir A; Wyczechowska, Dorota et al. (2015) Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies. Cancer Immunol Res 3:1236-47
Dimitriades, Victoria; Rodriguez, Paulo C; Zabaleta, Jovanny et al. (2014) Arginase I levels are decreased in the plasma of pediatric patients with atopic dermatitis. Ann Allergy Asthma Immunol 113:271-5
Crittenden, Marka R; Savage, Talicia; Cottam, Benjamin et al. (2014) Expression of arginase I in myeloid cells limits control of residual disease after radiation therapy of tumors in mice. Radiat Res 182:182-90
Srivastava, Ratika; Geng, Degui; Liu, Yingjia et al. (2012) Augmentation of therapeutic responses in melanoma by inhibition of IRAK-1,-4. Cancer Res 72:6209-16
Raber, Patrick; Ochoa, Augusto C; Rodriguez, Paulo C (2012) Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives. Immunol Invest 41:614-34
Naura, Amarjit S; Zerfaoui, Mourad; Kim, Hogyoung et al. (2010) Requirement for inducible nitric oxide synthase in chronic allergen exposure-induced pulmonary fibrosis but not inflammation. J Immunol 185:3076-85
Highfill, Steven L; Rodriguez, Paulo C; Zhou, Qing et al. (2010) Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. Blood 116:5738-47
Rodriguez, Paulo C; Hernandez, Claudia P; Morrow, Kevin et al. (2010) L-arginine deprivation regulates cyclin D3 mRNA stability in human T cells by controlling HuR expression. J Immunol 185:5198-204
Hernandez, Claudia P; Morrow, Kevin; Lopez-Barcons, Lluis A et al. (2010) Pegylated arginase I: a potential therapeutic approach in T-ALL. Blood 115:5214-21
Rodriguez, Paulo C; Ernstoff, Marc S; Hernandez, Claudia et al. (2009) Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 69:1553-60

Showing the most recent 10 out of 21 publications